Your session is about to expire
← Back to Search
18F-DCFPyL Injection for Cancer
Phase 1
Waitlist Available
Led By Steven Rowe, M.D., Ph.D
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
Summary
This trial will use a new imaging agent, 18F-DCFPyL, to detect none prostate cancer solid malignancies and schwannoma tumors using PET/CT.
Eligible Conditions
- Cancer
- Schwannoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Determine feasibility of using 18F-DCFPyL to detect cancer
Side effects data
From 2018 Phase 2 & 3 trial • 385 Patients • NCT029813681%
pyelonephritis, acute
1%
spinal cord compression
1%
atrial fibrillation
1%
hyperkalaemia
1%
coronary artery disease
1%
Lower gastrointestinal haemmorhage
1%
dysgeusia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Recurrent or Metastatic Prostate Cancer (Cohort B)
High Risk Prostate Cancer (Cohort A)
Trial Design
1Treatment groups
Experimental Treatment
Group I: 18F-DCFPyLExperimental Treatment1 Intervention
A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-DCFPyL Injection
2015
Completed Phase 3
~480
Find a Location
Who is running the clinical trial?
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
563 Previous Clinical Trials
33,286 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,959,363 Total Patients Enrolled
Steven Rowe, M.D., Ph.DPrincipal InvestigatorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Share this study with friends
Copy Link
Messenger